$3.37
7.67% yesterday
Nasdaq, Sep 27, 10:18 pm CET
ISIN
US70465T1079
Symbol
PDSB
Sector
Industry

PDS Biotechnology Corp. Stock price

$3.37
+0.25 8.01% 1M
-0.48 12.47% 6M
-1.60 32.19% YTD
-1.73 33.92% 1Y
-13.01 79.43% 3Y
-0.11 3.28% 5Y
-255.43 98.70% 10Y
Nasdaq, Closing price Fri, Sep 27 2024
+0.24 7.67%
ISIN
US70465T1079
Symbol
PDSB
Sector
Industry

Key metrics

Market capitalization $115.25m
Enterprise Value $81.90m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 3.72
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-39.71m
Free Cash Flow (TTM) Free Cash Flow $-34.46m
Cash position $57.73m
EPS (TTM) EPS $-1.23
P/E forward negative
Short interest 13.38%
Show more

Is PDS Biotechnology Corp. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.

PDS Biotechnology Corp. Stock Analysis

Unlock Scores for Free

Analyst Opinions

5 Analysts have issued a PDS Biotechnology Corp. forecast:

5x Buy
100%

Analyst Opinions

5 Analysts have issued a PDS Biotechnology Corp. forecast:

Buy
100%

Financial data from PDS Biotechnology Corp.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
- -
-
100%
- Direct Costs 0.06 0.06
77% 77%
-
-0.06 -0.06
77% 77%
-
- Selling and Administrative Expenses 14 14
8% 8%
-
- Research and Development Expense 25 25
27% 27%
-
-40 -40
17% 17%
-
- Depreciation and Amortization 0.06 0.06
77% 77%
-
EBIT (Operating Income) EBIT -40 -40
18% 18%
-
Net Profit -41 -41
15% 15%
-

In millions USD.

Don't miss a Thing! We will send you all news about PDS Biotechnology Corp. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

PDS Biotechnology Corp. Stock News

Positive
Seeking Alpha
4 days ago
PDS Biotechnology is focusing on an HPV-directed immunotherapy as its main near-term hope, with new data presented at the ESMO Congress. Strengths include promising clinical data and a focused pipeline, while risks involve typical biotech uncertainties and financial sustainability. The bottom-line summary suggests a cautious yet optimistic outlook, emphasizing the importance of upcoming clinica...
Neutral
GlobeNewsWire
19 days ago
PRINCETON, N.J., Sept. 09, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious disease vaccines, will present updated data from the VERSATILE-002 trial evaluating first-line treatment with Versamune® HPV ...
Neutral
GlobeNewsWire
25 days ago
PRINCETON, N.J., Sept. 03, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious disease vaccines, today announced that Frank Bedu-Addo, PhD, President and Chief Executive Officer of PDS Biotech will presen...
More PDS Biotechnology Corp. News

Company Profile

PDS Biotechnology Corp. engages in the development of clinical-stage immunotherapies to treat various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products PDS0101, is an off the shelf immunotherapeutic that is administered by subcutaneous injection. The company was founded by Frank K. Bedu-Addo on March 15, 2019 and is headquartered in Princeton, NJ.

Head office United States
CEO Frank Bedu-Addo
Employees 25
Founded 2005
Website www.pdsbiotech.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today